Company news
Percheron Therapeutics Limited news in 2020
Percheron Therapeutics Limited's news releases, calls and decks from 2020, newest first.
Annual General Meeting Chairmans Address
December 17, 2020
EC grants Orphan Drug Designation for ATL1102 in DMD
December 13, 2020
Receipt of R&D Tax Incentive payment
December 7, 2020
ANP raises A$7.3 million from Oversubscribed Placement
November 10, 2020
ANP to apply for dual listing on Frankfurt Stock Exchange
November 8, 2020
ANP receives US FDA ODD for ATL1102 in DMD
October 25, 2020
Pause in Trading
October 22, 2020
ATL1102 shows significant improvement vs external control
October 1, 2020
US FDA Grants RPDD to ATL1102 for the treatment of DMD
September 30, 2020
Antisense to present new data at WMS Virtual Congress 2020
September 29, 2020
ANP Submits EU Orphan Drug application for ATL1102 in DMD
August 30, 2020
ANP Submits US Orphan Drug application for ATL1102 in DMD
August 2, 2020
EMA DMD Scientific Advice and Regulatory Process Update
July 29, 2020
Trial Met Primary & Exceeded Secondary Endpoint Expectations
May 21, 2020
Appointment of US-based Consultant Medical Director
February 26, 2020
Results in DMD unlock value creation potential of ATL1102
February 5, 2020
Quarterly Update & Appendix 4C
January 30, 2020
Antisense Therapeutics Limited - Listed Options raise $5.5M
January 3, 2020